Skip to content

Vaxcyte, Inc. PCVX Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Merck & Co. logo
Merck & Co.MRK
Moderna logo
ModernaMRNA
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s preferred stock, shares authorized?
Vaxcyte, Inc. (PCVX) reported preferred stock, shares authorized of $10M in Q1 2026.
How has Vaxcyte, Inc.'s preferred stock, shares authorized changed year-over-year?
Vaxcyte, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Vaxcyte, Inc.'s preferred stock, shares authorized?
Over 2 years (2023 to 2025), Vaxcyte, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.